All In Biotech

Drug Trial Radar · NCT05879107

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

A Phase III, Open-label, Randomized, Controlled, Multi-Country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co Administered With PCV20 in Adults Aged 60\xa0Years and Older

Last checked: Nov 20, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,113

Actual

Start

May 26, 2023

Primary completion

Dec 6, 2023

Study completion May 7, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA investigational vaccineBiological

    One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).

  • PCV20Biological

    One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Geometric Mean Titers (GMT) of Opsonophagocytic (OP) Titers at 1 Month After the PCV20 VaccinationTime frame: At Day 31
  2. Adjusted GMTs of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers [Estimated Dilution 60 (ED60)] at 1 Month After the RSVPreF3 OA VaccinationTime frame: At Day 31 for Co-administration Group and at Day 61 for Control Group
  3. Adjusted GMTs of RSV-B Neutralizing Titers (ED60) at 1 Month After the RSVPreF3 OA VaccinationTime frame: At Day 31 for Co-administration Group and at Day 61 for Control Group

Locations

38 sites in 4 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Guntersville, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Huntington Beach, California

  • GSK Investigational Site

    Modesto, California

  • GSK Investigational Site

    Hamden, Connecticut

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    DeLand, Florida

  • GSK Investigational Site

    Jupiter, Florida

  • GSK Investigational Site

    Largo, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    West Des Moines, Iowa

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Troy, Michigan

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    North Charleston, South Carolina

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Frisco, Texas

  • GSK Investigational Site

    Mesquite, Texas

  • GSK Investigational Site

    Plano, Texas

  • GSK Investigational Site

    Antwerp, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Kluisbergen, Belgium

  • GSK Investigational Site

    Mechelen, Belgium

  • GSK Investigational Site

    Namur, Belgium

  • GSK Investigational Site

    Wetteren, Belgium

  • GSK Investigational Site

    Krakow, Poland

  • GSK Investigational Site

    Lodz, Poland

  • GSK Investigational Site

    Lublin, Poland

  • GSK Investigational Site

    Pu?awy, Poland

  • GSK Investigational Site

    Staszów, Poland

  • GSK Investigational Site

    Warsaw, Poland

  • GSK Investigational Site

    Warsaw, Poland

  • GSK Investigational Site

    Warsaw, Poland

  • GSK Investigational Site

    Wroclaw, Poland

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.